Skip to main content

Table 1 Main features of all included studies for diagnosis and prognosis

From: The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Id lncRNAs Author Year Country Duration of research Number of Patients (high/low) Sum of Patients Expression in Tumor Internal reference Method Cut-off Quality Score Follow-up (Month) Sample Outcome
1 TMED11P Zhenfei Zhu 2016 China 2007–2013 21/57 78 Down-regulation U6 qRT-PCR Median 7 60 Tissue OS
2 LOC389641 Shangyou Zheng 2015 China 2008–2015 53/53 106 Up-regulation GAPDH qRT-PCR Median 8 72 Tissue OS
6 HMlincRNA717 X.L.SUN 2016 China 2005–2011 74/76 150 Down-regulation U6 qRT-PCR Median 7 70 Tissue OS
7 ATB Shibin Qu 2015 China No 75/75 150 Down-regulation β-Actin qRT-PCR Median 8 60 Tissue OS
8 CCDC26 Wei Peng 2016 China 2011–2015 20/20 40 Up-regulation GAPDH qRT-PCR Median 7 60 Tissue OS
9 uc.345 Chao Liu 2016 China 2011–2013 68/35 103 Up-regulation RNU6B qRT-PCR Median 6 50 Tissue OS
11 Linc-pint Le Li 2016 China 2008–2011 28/23 51 Down-regulation GAPDH qRT-PCR Median 8 60 Plasma OS
17 AFAP1-AS1 Xue-Liang Fu 2016 China 2012–2014 40/40 80 Up-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
17 UCA1 Xue-Liang Fu 2016 China 2012–2014 40/40 80 Up-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
17 ENSG00000218510 Xue-Liang Fu 2016 China 2012–2014 40/40 80 Down-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
17 CRNDE Xue-Liang Fu 2016 China 2012–2014 40/40 80 Up-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
17 NR_036488 Xue-Liang Fu 2016 China 2012–2014 40/40 80 Up-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
17 ENSG00000244649 Xue-Liang Fu 2016 China 2012–2014 40/40 80 Up-regulation GAPDH qRT-PCR Median 8 50–60 Tissue OS
18 UCA1 Ping Chen 2016 China 2006–2009 64/64 128 Up-regulation GAPDH qRT-PCR Mean 8 60 Tissue OS
23 HOTTIP-005 Yingxue Wang 2015 China 2006–2014 118/26 144 Up-regulation GAPDH & β-Actin qRT-PCR Median 8 60 Tissue OS
23 XLOC_006390 Yingxue Wang 2015 China 2006–2014 110/34 144 Up-regulation GAPDH & β-Actin qRT-PCR Median 8 60 Tissue OS
23 RP11-567G11.1 Yingxue Wang 2015 China 2006–2014 96/48 144 Up-regulation GAPDH & β-Actin qRT-PCR Median 8 60 Tissue OS
24 MALAT1 Er-Jun Pang 2014 China No 63/63 126 Up-regulation β-Actin qRT-PCR Median 7 60 Tissue OS
38 ENST00000480739 Y-W Sun 2014 China No 20/15 35 Down-regulation β-Actin qRT-PCR Median 8 30 Tissue OS
39 HULC Wei Peng 2014 China 2006–2010 212/92 304 Up-regulation GAPDH qRT-PCR No 7 60 Tissue OS
40 MALAT1 Jiang-Hua Liu 2014 China 2010–2011 26/19 45 Up-regulation GAPDH qRT-PCR Mean 8 40 Tissue DSS
41 BC008363 Jiao Li 2014 China 2009- 2010 17/13 30 Down-regulation GAPDH qRT-PCR Median 8 30 Tissue OS
43 LOC285194 Yue-Chao Ding 2014 China 2004–2009 45/40 85 Down-regulation GAPDH qRT-PCR Mean 6 60 Tissue  
50 C/EBPb Chen-Song Huang 2017 China 2008–2013 54/29 83 Up-regulation NO qRT-PCR Mean 7 100 Tissue OS/DFS
50 LINC01133 Chen-Song Huang 2018 China 2015–2017 88/89 177 Up-regulation NO qRT-PCR Mean 8 100 Tissue OS/DFS
59 DUXAP8 Yifan Lian 2018 China 2007–2012 29/29 58 Up-regulation GAPDH qRT-PCR median 7 60 Tissue OS
67 CASC2 Yaqun Yu 2017 China No 56/54 110 Down-regulated RNU6B qRT-PCR Median 7 48 Tissue OS
76 DANCR Lei Chen 2018 China No 86/120 206 Up-regulation GAPDH qRT-PCR Mean 8 72 Tissue OS/PFS
83 LINC00346 Wan-Xin Peng 2019 China No 46/131 177 Up-regulation GAPDH qRT-PCR No 4 80 Tissue OS
103 XIST Wei Wei 2017 China No 32/32 64 Up-regulation RNU6B qRT-PCR Median 8 30 Tissue OS
109 ABHD11-AS1 X. QIAO 2018 China 2010–2013 72/75 147 Up-regulation GAPDH qRT-PCR No 8 60 Tissue OS
112 DLEU1 Song Gao 2018 China 2012–2017 39/23 62 Up-regulation GAPDH qRT-PCR Median 8 60 Tissue OS
114 FEZF1‐AS1 Zheng‐Lin Ou 2019 China No 28/28 56 Up-regulation RNU6B qRT-PCR Median 7 60 Tissue OS
125 lnc-PCTST Yandong Wang 2018 China 2015–2016 24/24 48 Down-regulated β-Actin qRT-PCR Median 6 20 Tissue OS
126 MACC1-AS1 Chen Qi 2019 China No 49/49 98 Up-regulation β-Actin qRT-PCR No 6 100 Tissue OS
136 XLOC_000647 Hao Hu 2018 China 2015–2016 24/24 48 Down-regulated β-Actin qRT-PCR Median 7 20 Tissue OS
144 HOTTIP Ozkan Balcin 2018 Turkey 2006–2014 61/39 100 Up-regulation GAPDH Q qRT-PCR No 7 46 Tissue OS
152 MSC-AS1 Yunpeng Sun 2019 China No 23/22 45 Up-regulation GAPDH qRT-PCR Median 6 36 Tissue OS
159 Sox2ot Zhonghu Li 2018 China 2012–2016 31/30 61 Up-regulation NO qRT-PCR Median 8 50 Blood OS
162 SPRY4-IT1 Yue Yaoa 2018 China 2011–2012 26/20 46 Up-regulation GAPDH qRT-PCR No 7 60 Tissue OS
169 GSTM3TV2 Guangbing Xiong 2019 China No 100/80 180 Up-regulation GAPDH & U7 qRT-PCR No 8 80 Tissue OS
172 SNHG15 X.-B. GUO 2018 China No 82/89 171 Up-regulation GAPDH qRT-PCR Median 8 60 Tissue OS
185 HULC Zheng-Lin Ou 2019 China 2012–2014 NO 60 Up-regulation GAPDH qRT-PCR Median 8 40 Tissue OS
186 lncRNA-UFC1 Peng Liu 2019 China 2012–2015 19/29 48 Up-regulation U6 qRT-PCR Mean 8 60 Serum OS
187 FOXP4-AS1 Xiao-Guang Liu 2019 China No NO 112 Up-regulation NO NO Median 4 50 Tissue OS
188 PLACT1 Xiaofan Ren 2020 China 2008–2018 83/83 166 Up-regulation NO NO Median 7 60 Tissue OS
189 ENSG00000254041.1 Bo Chen 2020 China 2013–2014 35/35 70 Up-regulation GAPDH qRT-PCR Median 4 50 Tissue OS
  1. OS overall survival, RFS recurrence-free survival, DFS disease free survival, DSS disease specific survival, PFS prognosis free survival, TMED11P trafficking protein 11, pseudogene, lncRNA-ATB long non-coding RNA-activated by transforming growth factor β, AFAP1-AS1 actin filament-associated protein 1 antisense RNA 1, UCA1 urothelial carcinoma associated 1 RNA, CRNDE Colorectal neoplasia differentially expressed, HOTTIP HOXA transcript at the distal tip, Malat1 metastasis associated lung adenocarcinoma transcript 1, CASC2 Cancer susceptibility candidate 2, DANCR Differentiation antagonizing non-protein coding RNA, XIST X-inactive specific transcript, SNHG16 small nucleolar RNA host gene 16, HULC Highly up‐regulated in liver cancer, qRT-PCR quantitative real-time polymerase chain reaction, NA not applicable